Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00088634
Status:
COMPLETED
Last Update Posted:
2016-04-08
First Post:
2004-07-30
Brief Title:
A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia
Sponsor:
Sumitomo Pharma America Inc
Organization:
Sumitomo Pharma America Inc
Study Overview
Official Title:
A Double-blind Fixed-dose Study of Lurasidone SM-13496 and Placebo in the Treatment of Schizophrenia
Status:
COMPLETED
Status Verified Date:
2016-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A 6-week in-patient and out-patient study to test the effectiveness and safety of a new medication in the treatment of schizophrenia
Detailed Description:
Study will evaluate the efficacy of a new compound versus placebo in the treatment of patients with schizophrenia diagnosed by DSM-IV criteria as measured by reductions from baseline on the total score of the Brief Psychiatric Rating Scale BPRS as extracted from the Positive and Negative Syndrome Scale PANSS
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None